Onychomycosis is a fungal infection of the nail, causing discoloration and thickening of the affected nail plate. As per the Delveinsight, the Onychomycosis prevalent population in the United States was found to be 35,829,110 in 2017. It is observed that adults and the elderly are more likely to suffer from Onychomycosis when compared to children and adolescents.
In 2017, the Onychomycosis market size in the 7MM [i.e. the United States, EU5 (Spain, Germany, Italy, France, and the UK) and Japan] was USD 3842.6 million. Clinical advancements, encouraging results of emerging therapies, and wide acceptance of topical therapies are some of the key drivers of the Onychomycosis market.
Some of the key companies in the Onychomycosis market include Moberg Pharma, Blueberry Therapeutics, Mycovia Pharmaceuticals, Meiji Seika Pharma, NovaBiotics, and others.
For more detailed information, visit: Onychomycosis Market Size